

# Charlotte E Teunissen

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4340247/charlotte-e-teunissen-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

523  
papers

16,759  
citations

63  
h-index

113  
g-index

635  
ext. papers

22,357  
ext. citations

5.5  
avg, IF

6.57  
L-index

#	Paper	IF	Citations
523	Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 1924-38	27.4	842
522	Neurofilaments as biomarkers in neurological disorders. <i>Nature Reviews Neurology</i> , <b>2018</b> , 14, 577-589	15	627
521	A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. <i>Neurology</i> , <b>2009</b> , 73, 1914-22	6.5	470
520	Macrophages in inflammatory multiple sclerosis lesions have an intermediate activation status. <i>Journal of Neuroinflammation</i> , <b>2013</b> , 10, 35	10.1	316
519	The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers. <i>Alzheimeris and Dementia</i> , <b>2011</b> , 7, 386-395.e6	1.2	291
518	CSF biomarker variability in the Alzheimer's Association quality control program. <i>Alzheimeris and Dementia</i> , <b>2013</b> , 9, 251-61	1.2	289
517	Alzheimer's disease. <i>Lancet, The</i> , <b>2021</b> , 397, 1577-1590	40	245
516	Optimizing patient care and research: the Amsterdam Dementia Cohort. <i>Journal of Alzheimeris Disease</i> , <b>2014</b> , 41, 313-27	4.3	243
515	Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. <i>JAMA Neurology</i> , <b>2019</b> , 76, 1035-1048	17.2	237
514	Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. <i>Nature Medicine</i> , <b>2020</b> , 26, 387-397	50.5	236
513	Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. <i>Biomarkers in Medicine</i> , <b>2012</b> , 6, 419-30	2.3	230
512	Inflammation markers in relation to cognition in a healthy aging population. <i>Journal of Neuroimmunology</i> , <b>2003</b> , 134, 142-50	3.5	224
511	A Practical Guide to Immunoassay Method Validation. <i>Frontiers in Neurology</i> , <b>2015</b> , 6, 179	4.1	223
510	Cerebrospinal fluid markers for differential dementia diagnosis in a large memory clinic cohort. <i>Neurology</i> , <b>2012</b> , 78, 47-54	6.5	220
509	Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimeris and Dementia</i> , <b>2012</b> , 8, 65-73	1.2	210
508	The cerebrospinal fluid "Alzheimer profile": easily said, but what does it mean?. <i>Alzheimeris and Dementia</i> , <b>2014</b> , 10, 713-723.e2	1.2	204
507	Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. <i>Alzheimeris and Dementia</i> , <b>2015</b> , 11, 1180-90	1.2	201

506	Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. <i>Lancet Neurology, The</i> , <b>2005</b> , 4, 32-41	24.1	199
505	Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 1013-24	5	181
504	Technical performance of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of $\beta$ -amyloid (1-42) in human cerebrospinal fluid. <i>Alzheimeris and Dementia</i> , <b>2016</b> , 12, 517-26	1.2	179
503	Proteomic analysis of cerebrospinal fluid extracellular vesicles: a comprehensive dataset. <i>Journal of Proteomics</i> , <b>2014</b> , 106, 191-204	3.9	172
502	Neurofilament light chain: a biomarker for genetic frontotemporal dementia. <i>Annals of Clinical and Translational Neurology</i> , <b>2016</b> , 3, 623-36	5.3	163
501	Biochemical markers related to Alzheimer's dementia in serum and cerebrospinal fluid. <i>Neurobiology of Aging</i> , <b>2002</b> , 23, 485-508	5.6	159
500	Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. <i>Neurology</i> , <b>2009</b> , 72, 1322-9	6.5	155
499	Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias: Update and areas of immediate need. <i>Alzheimeris and Dementia</i> , <b>2019</b> , 15, 292-312	1.2	155
498	Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer Disease. <i>JAMA Neurology</i> , <b>2015</b> , 72, 1275-80	17.2	152
497	Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry. <i>World Journal of Biological Psychiatry</i> , <b>2018</b> , 19, 244-328	3.8	148
496	Neurofilaments as biomarkers in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 552-6	5	148
495	Oligomeric and phosphorylated alpha-synuclein as potential CSF biomarkers for Parkinson's disease. <i>Molecular Neurodegeneration</i> , <b>2016</b> , 11, 7	19	140
494	Cerebrospinal fluid A $\beta$ 2 is the best predictor of clinical progression in patients with subjective complaints. <i>Alzheimeris and Dementia</i> , <b>2013</b> , 9, 481-7	1.2	139
493	Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes. <i>Annals of Neurology</i> , <b>2018</b> , 84, 648-658	9.4	137
492	The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative. <i>Alzheimeris and Dementia</i> , <b>2014</b> , 10, 808-17	1.2	132
491	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. <i>Neurology</i> , <b>2013</b> , 80, 1048-56	6.5	131
490	Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study. <i>Alzheimeris and Dementia</i> , <b>2016</b> , 12, 154-163	1.2	129
489	Consensus guidelines for lumbar puncture in patients with neurological diseases. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2017</b> , 8, 111-126	5.2	128

488	Associations between cerebral small-vessel disease and Alzheimer disease pathology as measured by cerebrospinal fluid biomarkers. <i>JAMA Neurology</i> , <b>2014</b> , 71, 855-62	17.2	113
487	Injury markers predict time to dementia in subjects with MCI and amyloid pathology. <i>Neurology</i> , <b>2012</b> , 79, 1809-16	6.5	110
486	Preclinical AD predicts decline in memory and executive functions in subjective complaints. <i>Neurology</i> , <b>2013</b> , 81, 1409-16	6.5	104
485	Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. <i>Brain</i> , <b>2015</b> , 138, 918-31	11.2	103
484	Consensus definitions and application guidelines for control groups in cerebrospinal fluid biomarker studies in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 1802-9	5	99
483	Mild cognitive impairment with suspected nonamyloid pathology (SNAP): Prediction of progression. <i>Neurology</i> , <b>2015</b> , 84, 508-15	6.5	96
482	Association of Cerebral Amyloid- $\beta$ Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , <b>2018</b> , 75, 84-95	14.5	94
481	Concordance between cerebrospinal fluid biomarkers and [ $^{11}\text{C}$ ]PIB PET in a memory clinic cohort. <i>Journal of Alzheimer's Disease</i> , <b>2014</b> , 41, 801-7	4.3	93
480	Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects. <i>Brain</i> , <b>2015</b> , 138, 2701-15.2	15.2	86
479	Brain network alterations in Alzheimer's disease measured by eigenvector centrality in fMRI are related to cognition and CSF biomarkers. <i>Human Brain Mapping</i> , <b>2014</b> , 35, 2383-93	5.9	84
478	In vivo detection of myelin proteins in cervical lymph nodes of MS patients using ultrasound-guided fine-needle aspiration cytology. <i>Journal of Neuroimmunology</i> , <b>2005</b> , 161, 190-4	3.5	83
477	Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. <i>Alzheimer's Research and Therapy</i> , <b>2015</b> , 7, 59	9	80
476	STABILITY OF INTERLEUKIN 6, SOLUBLE INTERLEUKIN 6 RECEPTOR, INTERLEUKIN 10 AND CC16 IN HUMAN SERUM. <i>Cytokine</i> , <b>2002</b> , 19, 228-235	4	79
475	Decreased levels of the brain specific 24S-hydroxycholesterol and cholesterol precursors in serum of multiple sclerosis patients. <i>Neuroscience Letters</i> , <b>2003</b> , 347, 159-62	3.3	77
474	Circulating metabolites and general cognitive ability and dementia: Evidence from 11 cohort studies. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 707-722	1.2	76
473	Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid- $\beta$ -42 Analysis Results. <i>Clinical Chemistry</i> , <b>2018</b> , 64, 576-585	5.5	76
472	Inflammatory biomarkers in Alzheimer's disease plasma. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 776-787	1.2	74
471	Selective impairment of hippocampus and posterior hub areas in Alzheimer's disease: an MEG-based multiplex network study. <i>Brain</i> , <b>2017</b> , 140, 1466-1485	11.2	72

470	Combination of serum markers related to several mechanisms in Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2003</b> , 24, 893-902	5.6	70
469	Cerebral perfusion in the predementia stages of Alzheimer's disease. <i>European Radiology</i> , <b>2016</b> , 26, 506-84		69
468	Neurofilament ELISA validation. <i>Journal of Immunological Methods</i> , <b>2010</b> , 352, 23-31	2.5	69
467	Serum neurofilament light chain in genetic frontotemporal dementia: a longitudinal, multicentre cohort study. <i>Lancet Neurology</i> , <b>2019</b> , 18, 1103-1111	24.1	68
466	Biobanking of CSF: international standardization to optimize biomarker development. <i>Clinical Biochemistry</i> , <b>2014</b> , 47, 288-92	3.5	68
465	Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2017</b> , 88, 113-118	5.5	66
464	Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 126-9	5.5	66
463	Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS. <i>Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders</i> , <b>2012</b> , 13, 1-10		65
462	EFNS guidelines on disease-specific CSF investigations. <i>European Journal of Neurology</i> , <b>2009</b> , 16, 760-70	6	65
461	Cerebrospinal fluid biomarkers of neurodegeneration in chronic neurological diseases. <i>Expert Review of Molecular Diagnostics</i> , <b>2008</b> , 8, 479-94	3.8	64
460	Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 5	9	63
459	Body fluid biomarkers for multiple sclerosis--the long road to clinical application. <i>Nature Reviews Neurology</i> , <b>2015</b> , 11, 585-96	15	62
458	Clinical value of neurofilament and phospho-tau/tau ratio in the frontotemporal dementia spectrum. <i>Neurology</i> , <b>2018</b> , 90, e1231-e1239	6.5	62
457	Discriminative and prognostic potential of cerebrospinal fluid phosphoTau/tau ratio and neurofilaments for frontotemporal dementia subtypes. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2015</b> , 1, 505-12	5.2	62
456	CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , <b>2013</b> , 19, 436-42	5	62
455	Plasma Amyloid- $\beta$ (A $\beta$ 2) Correlates with Cerebrospinal Fluid A $\beta$ 2 in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 62, 1857-1863	4.3	61
454	The impact of preanalytical variables on measuring cerebrospinal fluid biomarkers for Alzheimer's disease diagnosis: A review. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 1313-1333	1.2	61
453	Variability of CSF Alzheimer's disease biomarkers: implications for clinical practice. <i>PLoS ONE</i> , <b>2014</b> , 9, e100784	3.7	61

452	Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. <i>Alzheimeris and Dementia</i> , <b>2015</b> , 11, 1191-201	1.2	59
451	The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2016</b> , 87, 235-43	5.5	58
450	Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimer's Biomarkers in Daily Practice (ABIDE) Project. <i>JAMA Neurology</i> , <b>2017</b> , 74, 1481-1491	17.2	58
449	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. <i>Alzheimeris and Dementia</i> , <b>2019</b> , 15, 644-654	1.2	57
448	Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. <i>Alzheimeris Research and Therapy</i> , <b>2018</b> , 10, 76	9	56
447	Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach. <i>Neurobiology of Disease</i> , <b>2010</b> , 39, 229-41	7.5	56
446	Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer's disease. <i>Translational Psychiatry</i> , <b>2021</b> , 11, 27	8.6	55
445	Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. <i>Journal of Alzheimeris Disease</i> , <b>2012</b> , 29, 319-27	4.3	54
444	CSF neurofilaments in frontotemporal dementia compared with early onset Alzheimer's disease and controls. <i>Dementia and Geriatric Cognitive Disorders</i> , <b>2007</b> , 23, 225-30	2.6	54
443	Behavioural correlates of striatal glial fibrillary acidic protein in the 3-nitropropionic acid rat model: disturbed walking pattern and spatial orientation. <i>Neuroscience</i> , <b>2001</b> , 105, 153-67	3.9	54
442	Combination of plasma amyloid beta and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. <i>Alzheimeris Research and Therapy</i> , <b>2020</b> , 12, 118	9	54
441	Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM. <i>Journal of Proteomics</i> , <b>2013</b> , 78, 312-25	3.9	52
440	Oxysterols and cholesterol precursors correlate to magnetic resonance imaging measures of neurodegeneration in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2014</b> , 20, 412-7	5	52
439	Longitudinal cerebrospinal fluid biomarker trajectories along the Alzheimer's disease continuum in the BIOMARKAPD study. <i>Alzheimeris and Dementia</i> , <b>2019</b> , 15, 742-753	1.2	50
438	Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. <i>Journal of Alzheimeris Disease</i> , <b>2016</b> , 54, 287-95	4.3	50
437	HPA axis activity in multiple sclerosis correlates with disease severity, lesion type and gene expression in normal-appearing white matter. <i>Acta Neuropathologica</i> , <b>2013</b> , 126, 237-49	14.3	50
436	Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency. <i>Neurology</i> , <b>2010</b> , 75, 1617-22	6.5	50
435	Cholesterol and markers of cholesterol turnover in multiple sclerosis: relationship with disease outcomes. <i>Multiple Sclerosis and Related Disorders</i> , <b>2016</b> , 5, 53-65	4	49

434	β-synuclein species as potential cerebrospinal fluid biomarkers for dementia with lewy bodies. <i>Movement Disorders</i> , <b>2018</b> , 33, 1724-1733	7	49
433	Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline. <i>Brain</i> , <b>2018</b> , 141, 3443-3456	11.2	49
432	Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study. <i>Neurology</i> , <b>2016</b> , 86, 50-8	6.5	48
431	The impact of pre-analytical variables on the stability of neurofilament proteins in CSF, determined by a novel validated SinglePlex Luminex assay and ELISA. <i>Journal of Immunological Methods</i> , <b>2014</b> , 402, 43-9	2.5	48
430	Diagnostic impact of CSF biomarkers for Alzheimer's disease in a tertiary memory clinic. <i>Alzheimeris and Dementia</i> , <b>2015</b> , 11, 523-32	1.2	48
429	Safety, tolerability and efficacy of the glutaminy cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study. <i>Alzheimeris Research and Therapy</i> , <b>2018</b> , 10, 107	9	48
428	Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds. <i>Journal of Alzheimeris Disease</i> , <b>2015</b> , 48, 711-20	4.3	47
427	Novel diagnostic cerebrospinal fluid biomarkers for pathologic subtypes of frontotemporal dementia identified by proteomics. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2016</b> , 2, 86-94	5.2	46
426	Microbleeds relate to altered amyloid-β metabolism in Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2012</b> , 33, 1011.e1-9	5.6	46
425	Homocysteine: a marker for cognitive performance? A longitudinal follow-up study. <i>Journal of Nutrition, Health and Aging</i> , <b>2003</b> , 7, 153-9	5.2	46
424	Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts. <i>Alzheimeris and Dementia</i> , <b>2017</b> , 13, 1226-1236	1.2	45
423	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. <i>Lancet Neurology</i> , <b>2019</b> , 18, 1034-1044	24.1	45
422	Proteolytic shedding of the macrophage scavenger receptor CD163 in multiple sclerosis. <i>Journal of Neuroimmunology</i> , <b>2007</b> , 187, 179-86	3.5	45
421	How to handle adsorption of cerebrospinal fluid amyloid β(1-42) in laboratory practice? Identifying problematic handlings and resolving the issue by use of the Aβ/Aβ ratio. <i>Alzheimeris and Dementia</i> , <b>2017</b> , 13, 885-892	1.2	44
420	Serial CSF sampling in Alzheimer's disease: specific versus non-specific markers. <i>Neurobiology of Aging</i> , <b>2012</b> , 33, 1591-8	5.6	44
419	Identification of biomarkers for diagnosis and progression of MS by MALDI-TOF mass spectrometry. <i>Multiple Sclerosis Journal</i> , <b>2011</b> , 17, 838-50	5	44
418	Serum neurofilament light as a biomarker in progressive multiple sclerosis. <i>Neurology</i> , <b>2020</b> , 95, 436-444	6.5	44
417	Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2017</b> , 6, 143-151	5.2	43

416	Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. <i>Lancet Neurology, The</i> , <b>2021</b> , 20, 739-752	24.1	43
415	The Dutch Parelsoer Institute--Neurodegenerative diseases; methods, design and baseline results. <i>BMC Neurology</i> , <b>2014</b> , 14, 254	3.1	42
414	N-acetylaspartate and neurofilaments as biomarkers of axonal damage in patients with progressive forms of multiple sclerosis. <i>Journal of Neurology</i> , <b>2014</b> , 261, 2338-43	5.5	42
413	Standardization of Assay Procedures for Analysis of the CSF Biomarkers Amyloid ((1-42)), Tau, and Phosphorylated Tau in Alzheimer's Disease: Report of an International Workshop. <i>International Journal of Alzheimer's Disease</i> , <b>2010</b> , 2010,	3.7	42
412	24S-hydroxycholesterol in relation to disease manifestations of acute experimental autoimmune encephalomyelitis. <i>Journal of Neuroscience Research</i> , <b>2007</b> , 85, 1499-505	4.4	41
411	Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2015</b> , 36, 2340-7	5.6	40
410	Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression. <i>PLoS ONE</i> , <b>2013</b> , 8, e70019	3.7	40
409	Consensus Guidelines for CSF and Blood Biobanking for CNS Biomarker Studies. <i>Multiple Sclerosis International</i> , <b>2011</b> , 2011, 246412	1.1	40
408	Blood-based biomarkers for Alzheimer's disease: towards clinical implementation. <i>Lancet Neurology, The</i> , <b>2021</b> ,	24.1	40
407	Blood-based metabolic signatures in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2017</b> , 8, 196-207	5.2	39
406	The association of angiotensin-converting enzyme with biomarkers for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2014</b> , 6, 27	9	38
405	Elecsys Total-Tau and Phospho-Tau (181P) CSF assays: Analytical performance of the novel, fully automated immunoassays for quantification of tau proteins in human cerebrospinal fluid. <i>Clinical Biochemistry</i> , <b>2019</b> , 72, 30-38	3.5	37
404	Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease?. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2019</b> , 11, 383-391	5.2	37
403	Apolipoprotein A1 in Cerebrospinal Fluid and Plasma and Progression to Alzheimer's Disease in Non-Demented Elderly. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 56, 687-697	4.3	36
402	Prevalence of the apolipoprotein E $\epsilon$ 4 allele in amyloid $\beta$ positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 913-924	1.2	36
401	Upward drift in cerebrospinal fluid amyloid $\beta$ 42 assay values for more than 10 years. <i>Alzheimer's and Dementia</i> , <b>2018</b> , 14, 62-70	1.2	36
400	Serum leptin is not altered nor related to cognitive decline in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 44, 809-13	4.3	36
399	Brain-specific fatty acid-binding protein is elevated in serum of patients with dementia-related diseases. <i>European Journal of Neurology</i> , <b>2011</b> , 18, 865-71	6	36



398	Stability of interleukin 6, soluble interleukin 6 receptor, interleukin 10 and CC16 in human serum. <i>Cytokine</i> , <b>2002</b> , 19, 228-35	4	36
397	Unbiased estimates of cerebrospinal fluid $\beta$ amyloid 1-42 cutoffs in a large memory clinic population. <i>Alzheimer's Research and Therapy</i> , <b>2017</b> , 9, 8	9	35
396	Understanding multifactorial brain changes in type 2 diabetes: a biomarker perspective. <i>Lancet Neurology</i> , <b>2020</b> , 19, 699-710	24.1	35
395	Amyloid- $\beta$ oligomers relate to cognitive decline in Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 45, 35-43	4.3	34
394	Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases. <i>Methods</i> , <b>2012</b> , 56, 508-13	4.6	34
393	Serum homocysteine levels in relation to clinical progression in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2008</b> , 79, 1349-53	5.5	34
392	A novel quantification-driven proteomic strategy identifies an endogenous peptide of pleiotrophin as a new biomarker of Alzheimer's disease. <i>Scientific Reports</i> , <b>2017</b> , 7, 13333	4.9	33
391	Tracking disease progression non-invasively in Duchenne and Becker muscular dystrophies. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , <b>2018</b> , 9, 715-726	10.3	32
390	Applying the ATN scheme in a memory clinic population: The ABIDE project. <i>Neurology</i> , <b>2019</b> , 93, e1635-61646	6.16	32
389	Endogeneous peptide profiling of cerebrospinal fluid by MALDI-TOF mass spectrometry: Optimization of magnetic bead-based peptide capture and analysis of preanalytical variables. <i>Proteomics - Clinical Applications</i> , <b>2007</b> , 1, 1385-92	3.1	32
388	The effectiveness of aerobic training, cognitive behavioural therapy, and energy conservation management in treating MS-related fatigue: the design of the TREFAMS-ACE programme. <i>Trials</i> , <b>2013</b> , 14, 250	2.8	31
387	The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases. <i>Frontiers in Neurology</i> , <b>2015</b> , 6, 216	4.1	31
386	Oncolytic virotherapy in glioblastoma patients induces a tumor macrophage phenotypic shift leading to an altered glioblastoma microenvironment. <i>Neuro-Oncology</i> , <b>2018</b> , 20, 1494-1504	1	31
385	Plasma GFAP is an early marker of amyloid- $\beta$ but not tau pathology in Alzheimer's disease. <i>Brain</i> , <b>2021</b> ,	11.2	31
384	ATN classification and clinical progression in subjective cognitive decline: The SCIENCE project. <i>Neurology</i> , <b>2020</b> , 95, e46-e58	6.5	30
383	BRI2-BRICHOS is increased in human amyloid plaques in early stages of Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2014</b> , 35, 1596-604	5.6	30
382	SUCLG2 identified as both a determinant of CSF A $\beta$ -42 levels and an attenuator of cognitive decline in Alzheimer's disease. <i>Human Molecular Genetics</i> , <b>2014</b> , 23, 6644-58	5.6	30
381	Tau Rather than TDP-43 Proteins are Potential Cerebrospinal Fluid Biomarkers for Frontotemporal Lobar Degeneration Subtypes: A Pilot Study. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 55, 585-595	4.3	30

380	Diagnostic performance of Elecsys immunoassays for cerebrospinal fluid Alzheimer's disease biomarkers in a nonacademic, multicenter memory clinic cohort: The ABIDE project. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2018</b> , 10, 563-572	5.2	30
379	Clinical phenotype, atrophy, and small vessel disease in $\Delta$ carriers with Alzheimer disease. <i>Neurology</i> , <b>2018</b> , 91, e1851-e1859	6.5	30
378	Poly(GP), neurofilament and grey matter deficits in expansion carriers. <i>Annals of Clinical and Translational Neurology</i> , <b>2018</b> , 5, 583-597	5.3	29
377	White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation. <i>Alzheimeris Research and Therapy</i> , <b>2018</b> , 10, 30	9	29
376	Gray matter networks and clinical progression in subjects with predementia Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2018</b> , 61, 75-81	5.6	29
375	N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry. <i>Journal of Neurology</i> , <b>2007</b> , 254, 631-7	5.5	29
374	A metabolite-based machine learning approach to diagnose Alzheimer-type dementia in blood: Results from the European Medical Information Framework for Alzheimer disease biomarker discovery cohort. <i>Alzheimeris and Dementia: Translational Research and Clinical Interventions</i> , <b>2019</b> , 5, 933-938	6	29
373	Head-to-Head Comparison of 8 Plasma Amyloid- $\beta$ 2/40 Assays in Alzheimer Disease. <i>JAMA Neurology</i> , <b>2021</b> , 78, 1375-1382	17.2	29
372	Regulator of oligodendrocyte maturation, miR-219, a potential biomarker for MS. <i>Journal of Neuroinflammation</i> , <b>2017</b> , 14, 235	10.1	28
371	CSF or serum neurofilament light added to $\beta$ Synuclein panel discriminates Parkinson's from controls. <i>Movement Disorders</i> , <b>2020</b> , 35, 288-295	7	28
370	Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study. <i>Clinical Chemistry</i> , <b>2018</b> , 64, 927-937	5.5	27
369	Discordant amyloid- $\beta$ PET and CSF biomarkers and its clinical consequences. <i>Alzheimeris Research and Therapy</i> , <b>2019</b> , 11, 78	9	26
368	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimeris and Dementia</i> , <b>2019</b> , 15, 817-827	1.2	26
367	A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline. <i>Human Brain Mapping</i> , <b>2018</b> , 39, 3143-3151	5.9	26
366	Antibody-based methods for the measurement of $\beta$ Synuclein concentration in human cerebrospinal fluid - method comparison and round robin study. <i>Journal of Neurochemistry</i> , <b>2019</b> , 149, 126-138	6	26
365	Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. <i>Neurology</i> , <b>2014</b> , 83, 1210-6	6.5	26
364	Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study. <i>Multiple Sclerosis Journal</i> , <b>2020</b> , 26, 912-923	5	26
363	Gray matter network measures are associated with cognitive decline in mild cognitive impairment. <i>Neurobiology of Aging</i> , <b>2018</b> , 61, 198-206	5.6	25

362	Quantitative proteomics suggests decrease in the secretogranin-1 cerebrospinal fluid levels during the disease course of multiple sclerosis. <i>Proteomics</i> , <b>2015</b> , 15, 3361-9	4.8	25
361	The EMIF-AD PreclinAD study: study design and baseline cohort overview. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 75	9	24
360	Cerebrospinal fluid biomarker examination as a tool to discriminate behavioral variant frontotemporal dementia from primary psychiatric disorders. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2017</b> , 7, 99-106	5.2	23
359	Contactins in the central nervous system: role in health and disease. <i>Neural Regeneration Research</i> , <b>2019</b> , 14, 206-216	4.5	23
358	Cerebrospinal fluid proteomics and biological heterogeneity in Alzheimer's disease: A literature review. <i>Critical Reviews in Clinical Laboratory Sciences</i> , <b>2020</b> , 57, 86-98	9.4	23
357	Heterogeneous Language Profiles in Patients with Primary Progressive Aphasia due to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 51, 581-90	4.3	23
356	Characterising user preference for white LED light sources with CIE colour rendering index combined with a relative gamut area index. <i>Lighting Research and Technology</i> , <b>2017</b> , 49, 461-480	2	22
355	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 1478-1488	1.2	22
354	Personalized risk for clinical progression in cognitively normal subjects-the ABIDE project. <i>Alzheimer's Research and Therapy</i> , <b>2019</b> , 11, 33	9	22
353	Neuronal pentraxin 2: a synapse-derived CSF biomarker in genetic frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2020</b> , 91, 612-621	5.5	22
352	Influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2015</b> , 36, 1605.e13-20	5.6	22
351	Building a new paradigm for the early recognition of behavioral variant frontotemporal dementia: Late Onset Frontal Lobe Syndrome study. <i>American Journal of Geriatric Psychiatry</i> , <b>2014</b> , 22, 735-40	6.5	22
350	Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. <i>Alzheimer's and Dementia</i> , <b>2017</b> , 13, 903-912	1.2	21
349	Relation of Odor Identification with Alzheimer's Disease Markers in Cerebrospinal Fluid and Cognition. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 60, 1025-1034	4.3	21
348	Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 60, 1119-1128	4.3	21
347	Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier. <i>Frontiers in Aging Neuroscience</i> , <b>2018</b> , 10, 111	5.3	21
346	Cerebrospinal fluid and plasma clusterin levels in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , <b>2013</b> , 19, 1079-83	3.6	21
345	Comparison of ELISA- and SIMOA-based quantification of plasma A $\beta$ ratios for early detection of cerebral amyloidosis. <i>Alzheimer's Research and Therapy</i> , <b>2020</b> , 12, 162	9	21

344	Serum markers glial fibrillary acidic protein and neurofilament light for prognosis and monitoring in cognitively normal older people: a prospective memory clinic-based cohort study. <i>The Lancet Healthy Longevity</i> , <b>2021</b> , 2, e87-e95	9.5	21
343	Aβ4 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer's disease progression. <i>Nature Communications</i> , <b>2019</b> , 10, 2240	17.4	20
342	Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , <b>2017</b> , 9, 73	9	20
341	Discriminatory and predictive capabilities of enzyme-linked immunosorbent assay and multiplex platforms in a longitudinal Alzheimer's disease study. <i>Alzheimer's and Dementia</i> , <b>2013</b> , 9, 276-83	1.2	20
340	Multitracer model for staging cortical amyloid deposition using PET imaging. <i>Neurology</i> , <b>2020</b> , 95, e15386-15390	6.5	20
339	Sex differences in CSF biomarkers vary by Alzheimer disease stage and APOE genotype. <i>Neurology</i> , <b>2020</b> , 95, e2378-e2388	6.5	20
338	The plasma peptides of ovarian cancer. <i>Clinical Proteomics</i> , <b>2018</b> , 15, 41	5	20
337	Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [F]-Flutemetamol PET Scan Result. <i>Frontiers in Aging Neuroscience</i> , <b>2018</b> , 10, 409	5.3	20
336	Prevalence of abnormal Alzheimer's disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samples. <i>Alzheimer's Research and Therapy</i> , <b>2019</b> , 11, 8	9	19
335	Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment. <i>Multiple Sclerosis Journal</i> , <b>2018</b> , 24, 472-480	5	19
334	Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2018</b> , 61, 309-320	4.3	19
333	The neurofilament light chain is not stable in vitro. <i>Annals of Neurology</i> , <b>2011</b> , 69, 1065-6; author reply 1066-7	9.4	19
332	Growth-associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis. <i>Neuropathology and Applied Neurobiology</i> , <b>2006</b> , 32, 318-31	5.2	19
331	Evaluation of 3-nitrotyrosine as a marker for 3-nitropropionic acid-induced oxidative stress in Lewis and Wistar rats and strain-specific whole brain spheroid cultures. <i>Brain Research</i> , <b>2002</b> , 931, 5-20	3.7	19
330	Homocysteine in relation to cognitive performance in pathological and non-pathological conditions. <i>Clinical Chemistry and Laboratory Medicine</i> , <b>2005</b> , 43, 1089-95	5.9	19
329	Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer's Disease: Analytical and Diagnostic Characterization. <i>Journal of Alzheimer's Disease</i> , <b>2017</b> , 55, 159-170	4.3	19
328	Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease-Data from three memory clinic studies. <i>Alzheimer's and Dementia</i> , <b>2019</b> , 15, 185-193	1.2	19
327	CSF ApoE predicts clinical progression in nondemented APOEεε carriers. <i>Neurobiology of Aging</i> , <b>2017</b> , 57, 186-194	5.6	18

326	Glutaminy cyclase activity correlates with levels of A $\beta$ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients. <i>Alzheimer's Research and Therapy</i> , <b>2017</b> , 9, 38	9	18
325	Plasma amyloid is associated with the rate of cognitive decline in cognitively normal elderly: the SCIENCE project. <i>Neurobiology of Aging</i> , <b>2020</b> , 89, 99-107	5.6	18
324	Highly specific and ultrasensitive plasma test detects Abeta(1-42) and Abeta(1-40) in Alzheimer's disease. <i>Scientific Reports</i> , <b>2021</b> , 11, 9736	4.9	18
323	$\beta$ Synuclein evokes NLRP3 inflammasome-mediated IL-1 $\beta$ secretion from primary human microglia. <i>Glia</i> , <b>2021</b> , 69, 1413-1428	9	18
322	Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. <i>NeuroImage: Clinical</i> , <b>2018</b> , 19, 625-632	5.3	18
321	Effect of long-term storage in biobanks on cerebrospinal fluid biomarker A $\beta$ T-tau, and P-tau values. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2017</b> , 8, 45-50	5.2	17
320	Nutrients required for phospholipid synthesis are lower in blood and cerebrospinal fluid in mild cognitive impairment and Alzheimer's disease dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2017</b> , 8, 139-146	5.2	17
319	Fingerprinting Alzheimer's Disease by H Nuclear Magnetic Resonance Spectroscopy of Cerebrospinal Fluid. <i>Journal of Proteome Research</i> , <b>2020</b> , 19, 1696-1705	5.6	17
318	Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 52, 51-64	4.3	17
317	Pre-amyloid stage of Alzheimer's disease in cognitively normal individuals. <i>Annals of Clinical and Translational Neurology</i> , <b>2018</b> , 5, 1037-1047	5.3	17
316	Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial. <i>Neurology</i> , <b>2020</b> , 95, e745-e754	6.5	17
315	Neurometabolite Alterations Associated With Cognitive Performance in Perinatally HIV-Infected Children. <i>Medicine (United States)</i> , <b>2016</b> , 95, e3093	1.8	17
314	PET and CSF amyloid- $\beta$ status are differently predicted by patient features: information from discordant cases. <i>Alzheimer's Research and Therapy</i> , <b>2019</b> , 11, 100	9	17
313	Angiopoietin like-4 as a novel vascular mediator in capillary cerebral amyloid angiopathy. <i>Brain</i> , <b>2018</b> , 141, 3377-3388	11.2	17
312	A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/A $\beta$ 2 cutoff with concordance to amyloid positron emission tomography imaging. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2017</b> , 6, 201-209	5.2	16
311	Associations of AD Biomarkers and Cognitive Performance with Nutritional Status: The NUDAD Project. <i>Nutrients</i> , <b>2019</b> , 11,	6.7	16
310	Identification of novel cerebrospinal fluid biomarker candidates for dementia with Lewy bodies: a proteomic approach. <i>Molecular Neurodegeneration</i> , <b>2020</b> , 15, 36	19	16
309	Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions. <i>Neurobiology of Aging</i> , <b>2019</b> , 84, 225-234	5.6	16

308	Facilitating the Validation of Novel Protein Biomarkers for Dementia: An Optimal Workflow for the Development of Sandwich Immunoassays. <i>Frontiers in Neurology</i> , <b>2015</b> , 6, 202	4.1	16
307	Neurofilament stoichiometry simulations during neurodegeneration suggest a remarkable self-sufficient and stable in vivo protein structure. <i>Journal of the Neurological Sciences</i> , <b>2011</b> , 307, 132-8	3.2	16
306	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. <i>Brain</i> , <b>2020</b> , 143, 3776-3792	11.2	16
305	Angiotensin-converting enzyme in cerebrospinal fluid and risk of brain atrophy. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 44, 153-62	4.3	15
304	Validation of soluble amyloid- $\beta$ precursor protein assays as diagnostic CSF biomarkers for neurodegenerative diseases. <i>Journal of Neurochemistry</i> , <b>2016</b> , 137, 112-21	6	15
303	Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change. <i>Journal of Psychiatric Research</i> , <b>2018</b> , 104, 183-191	5.2	15
302	Retinal thickness as a potential biomarker in patients with amyloid-proven early- and late-onset Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2019</b> , 11, 463-471	5.2	15
301	VGF Peptides in Cerebrospinal Fluid of Patients with Dementia with Lewy Bodies. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	15
300	Role of BRI2 in dementia. <i>Journal of Alzheimer's Disease</i> , <b>2014</b> , 40, 481-94	4.3	15
299	Serum Neurofilament light correlates with CADASIL disease severity and survival. <i>Annals of Clinical and Translational Neurology</i> , <b>2019</b> , 6, 46-56	5.3	15
298	Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. <i>BMC Geriatrics</i> , <b>2018</b> , 18, 289	4.1	15
297	Comparison of multiplex platforms for cytokine assessments and their potential use for biomarker profiling in multiple sclerosis. <i>Cytokine</i> , <b>2017</b> , 91, 145-152	4	14
296	Low normal cerebrospinal fluid A $\beta$ 2 levels predict clinical progression in nondemented subjects. <i>Annals of Neurology</i> , <b>2017</b> , 81, 749-753	9.4	14
295	Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy. <i>Multiple Sclerosis Journal</i> , <b>2015</b> , 21, 481-4	5	14
294	Cerebrospinal fluid apolipoprotein E and phospholipid transfer protein activity are reduced in multiple sclerosis; relationships with the brain MRI and CSF lipid variables. <i>Multiple Sclerosis and Related Disorders</i> , <b>2014</b> , 3, 533-541	4	14
293	cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases. <i>International Journal of Alzheimer's Disease</i> , <b>2010</b> , 2010,	3.7	14
292	Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , 13, 198	9	14
291	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , <b>2019</b> , 90, 997-1004	5.5	13

290	APOE $\epsilon$ genotype-dependent cerebrospinal fluid proteomic signatures in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2020</b> , 12, 65	9	13
289	Disease-related determinants are associated with mortality in dementia due to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 23	9	13
288	Vascular Endothelial Growth Factor remains unchanged in cerebrospinal fluid of patients with Alzheimer's disease and vascular dementia. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 58	9	13
287	Whole brain spheroid cultures as a model to study the development of nitric oxide synthase-guanylate cyclase signal transduction. <i>Developmental Brain Research</i> , <b>2000</b> , 125, 99-115		13
286	Evaluation of a novel immunoassay to detect p-tau Thr217 in the CSF to distinguish Alzheimer disease from other dementias. <i>Neurology</i> , <b>2020</b> , 95, e3026-e3035	6.5	13
285	Detection of contactin-2 in cerebrospinal fluid (CSF) of patients with Alzheimer's disease using Fluorescence Correlation Spectroscopy (FCS). <i>Clinical Biochemistry</i> , <b>2017</b> , 50, 1061-1066	3.5	13
284	Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression. <i>Movement Disorders</i> , <b>2020</b> , 35, 859-867	7	13
283	Design of the ExCersion-VCI study: The effect of aerobic exercise on cerebral perfusion in patients with vascular cognitive impairment. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2017</b> , 3, 157-165	6	12
282	ApoE and clusterin CSF levels influence associations between APOE $\epsilon$ genotype and changes in CSF tau, but not CSF A $\beta$ 2, levels in non-demented elderly. <i>Neurobiology of Aging</i> , <b>2019</b> , 79, 101-109	5.6	12
281	CNS penetration of ART in HIV-infected children. <i>Journal of Antimicrobial Chemotherapy</i> , <b>2018</b> , 73, 484-489	4.9	12
280	Contactin-2, a synaptic and axonal protein, is reduced in cerebrospinal fluid and brain tissue in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 52	9	12
279	Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers. <i>Journal of Alzheimer's Disease</i> , <b>2016</b> , 50, 261-70	4.3	12
278	Increased plasma 8,12-iso-iPF2alpha- VI levels in relapsing multiple sclerosis patients are not predictive of disease progression. <i>Multiple Sclerosis Journal</i> , <b>2012</b> , 18, 1092-8	5	12
277	Characterization of pre-analytical sample handling effects on a panel of Alzheimer's disease-related blood-based biomarkers: Results from the Standardization of Alzheimer's Blood Biomarkers (SABB) working group. <i>Alzheimer's and Dementia</i> , <b>2021</b> ,	1.2	12
276	Specific Nutritional Biomarker Profiles in Mild Cognitive Impairment and Subjective Cognitive Decline Are Associated With Clinical Progression: The NUDAD Project. <i>Journal of the American Medical Directors Association</i> , <b>2020</b> , 21, 1513.e1-1513.e17	5.9	12
275	The Alzheimer's Association international guidelines for handling of cerebrospinal fluid for routine clinical measurements of amyloid $\beta$ and tau. <i>Alzheimer's and Dementia</i> , <b>2021</b> , 17, 1575-1582	1.2	12
274	Detecting amyloid positivity in early Alzheimer's disease using combinations of plasma A $\beta$ 2/A $\beta$ 0 and p-tau. <i>Alzheimer's and Dementia</i> , <b>2021</b> ,	1.2	12
273	Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis. <i>Neurology</i> , <b>2021</b> , 97, e1898-e1905	6.5	12

272	Regional [ <sup>18</sup> F]flortaucipir PET is more closely associated with disease severity than CSF p-tau in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2020</b> , 47, 2866-2878	8.8	11
271	Monocyte-derived tissue transglutaminase in multiple sclerosis patients: reflecting an anti-inflammatory status and function of the cells?. <i>Journal of Neuroinflammation</i> , <b>2017</b> , 14, 257	10.1	11
270	The use of cerebrospinal fluid in biomarker studies. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2017</b> , 146, 3-20	3	11
269	Plasma proteome in multiple sclerosis disease progression. <i>Annals of Clinical and Translational Neurology</i> , <b>2019</b> , 6, 1582-1594	5.3	11
268	Correcting for the Absence of a Gold Standard Improves Diagnostic Accuracy of Biomarkers in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2015</b> , 46, 889-99	4.3	11
267	Olfactory and gustatory functioning and food preferences of patients with Alzheimer's disease and mild cognitive impairment compared to controls: the NUDAD project. <i>Journal of Neurology</i> , <b>2020</b> , 267, 144-152	5.5	11
266	The plasma peptidome. <i>Clinical Proteomics</i> , <b>2018</b> , 15, 39	5	11
265	The Bri2 and Bri3 BRICHOS Domains Interact Differently with A $\beta$ and Alzheimer Amyloid Plaques. <i>Journal of Alzheimer's Disease Reports</i> , <b>2018</b> , 2, 27-39	3.3	11
264	Personalized B-cell tailored dosing of ocrelizumab in patients with multiple sclerosis during the COVID-19 pandemic. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211028833	5	11
263	Accumulation of BRI2-BRICHOS ectodomain correlates with a decreased clearance of A $\beta$ by insulin degrading enzyme (IDE) in Alzheimer's disease. <i>Neuroscience Letters</i> , <b>2015</b> , 589, 47-51	3.3	10
262	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 74, 213-225	4.3	10
261	CCL23: A Chemokine Associated with Progression from Mild Cognitive Impairment to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 73, 1585-1595	4.3	10
260	Amyloid- $\beta$ misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline. <i>Alzheimer's Research and Therapy</i> , <b>2020</b> , 12, 169	9	10
259	Amyloid- $\beta$ PET and CSF in an autopsy-confirmed cohort. <i>Annals of Clinical and Translational Neurology</i> , <b>2020</b> , 7, 2150-2160	5.3	10
258	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. <i>Translational Psychiatry</i> , <b>2020</b> , 10, 403	8.6	10
257	Multicenter immunoassay validation of cerebrospinal fluid neurofilament light: a biomarker for neurodegeneration. <i>Bioanalysis</i> , <b>2016</b> , 8, 2243-2254	2.1	10
256	Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease. <i>Journal of the International Neuropsychological Society</i> , <b>2021</b> , 27, 426-438	3.1	10
255	Neuronal and glial CSF biomarkers in multiple sclerosis: a systematic review and meta-analysis. <i>Reviews in the Neurosciences</i> , <b>2021</b> , 32, 573-595	4.7	10



254	Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2018</b> , 4, 2055217318819535	2	10
253	Association of amyloid pathology with memory performance and cognitive complaints in cognitively normal older adults: a monozygotic twin study. <i>Neurobiology of Aging</i> , <b>2019</b> , 77, 58-65	5.6	9
252	Standard biobanking conditions prevent evaporation of body fluid samples. <i>Clinica Chimica Acta</i> , <b>2015</b> , 442, 141-5	6.2	9
251	Biobanking of Cerebrospinal Fluid for Biomarker Analysis in Neurological Diseases. <i>Advances in Experimental Medicine and Biology</i> , <b>2015</b> , 864, 79-93	3.6	9
250	Arylesterase Activity of Paraoxonase-1 in Serum and Cerebrospinal Fluid of Patients with Alzheimer's Disease and Vascular Dementia. <i>Antioxidants</i> , <b>2020</b> , 9,	7.1	9
249	The appreciation of LED-based white light sources by Dutch and Chinese people in three application areas. <i>Lighting Research and Technology</i> , <b>2019</b> , 51, 353-372	2	9
248	Lumbar puncture in patients with neurologic conditions. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2017</b> , 8, 108-110	5.2	9
247	Multicenter Analytical Validation of A $\beta$ 0 Immunoassays. <i>Frontiers in Neurology</i> , <b>2017</b> , 8, 310	4.1	9
246	Concentrations of different sterols in the striatum and serum of 3-nitropropionic acid-treated Wistar and Lewis rats. <i>Neurochemical Research</i> , <b>2001</b> , 26, 1237-44	4.6	9
245	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum.. <i>JAMA Neurology</i> , <b>2022</b> ,	17.2	9
244	Energy intake and expenditure in patients with Alzheimer's disease and mild cognitive impairment: the NUDAD project. <i>Alzheimeris Research and Therapy</i> , <b>2020</b> , 12, 116	9	9
243	Diagnostic Value of the CSF $\beta$ synuclein Real-Time Quaking-Induced Conversion Assay at the Prodromal MCI Stage of Dementia With Lewy Bodies. <i>Neurology</i> , <b>2021</b> , 97, e930-e940	6.5	9
242	Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2021</b> , 8,	9.1	9
241	Novel CSF biomarkers to discriminate FTLD and its pathological subtypes. <i>Annals of Clinical and Translational Neurology</i> , <b>2018</b> , 5, 1163-1175	5.3	9
240	Guidelines for CSF Processing and Biobanking: Impact on the Identification and Development of Optimal CSF Protein Biomarkers. <i>Methods in Molecular Biology</i> , <b>2019</b> , 2044, 27-50	1.4	8
239	Systemic and intrathecal immune activation in association with cerebral and cognitive outcomes in paediatric HIV. <i>Scientific Reports</i> , <b>2019</b> , 9, 8004	4.9	8
238	Serum neurofilaments as candidate biomarkers of natalizumab associated progressive multifocal leukoencephalopathy. <i>Annals of Neurology</i> , <b>2019</b> , 86, 322-324	9.4	8
237	A multi-center study of neurofilament assay reliability and inter-laboratory variability. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , <b>2020</b> , 21, 452-458	3.6	8

236	Pre-analytical stability of novel cerebrospinal fluid biomarkers. <i>Clinica Chimica Acta</i> , <b>2019</b> , 497, 204-211	6.2	8
235	Biomarker research in multiple sclerosis: addressing axonal damage and heterogeneity. <i>Biomarkers in Medicine</i> , <b>2007</b> , 1, 111-9	2.3	8
234	Pathologically Decreased CSF Levels of Synaptic Marker NPTX2 in DLB Are Correlated with Levels of Alpha-Synuclein and VGF. <i>Cells</i> , <b>2020</b> , 10,	7.9	8
233	Decision tree supports the interpretation of CSF biomarkers in Alzheimer's disease. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2019</b> , 11, 1-9	5.2	8
232	Computer-assisted prediction of clinical progression in the earliest stages of AD. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2018</b> , 10, 726-736	5.2	8
231	Interlaboratory proficiency processing scheme in CSF aliquoting: implementation and assessment based on biomarkers of Alzheimer's disease. <i>Alzheimeris Research and Therapy</i> , <b>2018</b> , 10, 87	9	8
230	Neuropsychiatric and Cognitive Symptoms Across the Alzheimer Disease Clinical Spectrum: Cross-sectional and Longitudinal Associations. <i>Neurology</i> , <b>2021</b> , 97, e1276-e1287	6.5	8
229	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. <i>Journal of Alzheimeris Disease</i> , <b>2017</b> , 56, 543-555	4.3	7
228	Alzheimer disease biomarkers may aid in the prognosis of MCI cases initially reverted to normal. <i>Neurology</i> , <b>2019</b> , 92, e2699-e2705	6.5	7
227	Working memory moderates the relation between the brain-derived neurotropic factor (BDNF) and psychotherapy outcome for depression. <i>Journal of Psychiatric Research</i> , <b>2020</b> , 130, 424-432	5.2	7
226	Gut Microbiota Composition Is Related to AD Pathology.. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 794519	8.4	7
225	Techniques, Contraindications, and Complications of CSF Collection Procedures <b>2015</b> , 35-57		7
224	Plasma NFL and GFAP as biomarkers of spinal cord degeneration in adrenoleukodystrophy. <i>Annals of Clinical and Translational Neurology</i> , <b>2020</b> , 7, 2127-2136	5.3	7
223	Metabolic Age Based on the BBMRI-NL H-NMR Metabolomics Repository as Biomarker of Age-related Disease. <i>Circulation Genomic and Precision Medicine</i> , <b>2020</b> , 13, 541-547	5.2	7
222	Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results. <i>Alzheimeris Research and Therapy</i> , <b>2021</b> , 13, 53	9	7
221	Degree of genetic liability for Alzheimer's disease associated with specific proteomic profiles in cerebrospinal fluid. <i>Neurobiology of Aging</i> , <b>2020</b> , 93, 144.e1-144.e15	5.6	6
220	Current Approaches and Clinician Attitudes to the Use of Cerebrospinal Fluid Biomarkers in Diagnostic Evaluation of Dementia in Europe. <i>Journal of Alzheimeris Disease</i> , <b>2017</b> , 60, 201-210	4.3	6
219	Brain endothelial cell expression of SPARCL-1 is specific to chronic multiple sclerosis lesions and is regulated by inflammatory mediators in vitro. <i>Neuropathology and Applied Neurobiology</i> , <b>2018</b> , 44, 404-416	5.2	6

218	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. <i>Journal of Neurology</i> , <b>2019</b> , 266, 2535-2545	5.5	6
217	Inhaled carbon monoxide protects time-dependently from loss of hypoxic pulmonary vasoconstriction in endotoxemic mice. <i>Respiratory Research</i> , <b>2015</b> , 16, 119	7.3	6
216	State-of-the-art of lumbar puncture and its place in the journey of patients with Alzheimer's disease. <i>Alzheimeris and Dementia</i> , <b>2021</b> ,	1.2	6
215	Plasma amyloid- $\beta$ oligomerization assay as a pre-screening test for amyloid status. <i>Alzheimeris Research and Therapy</i> , <b>2021</b> , 13, 133	9	6
214	The plasma peptides of breast versus ovarian cancer. <i>Clinical Proteomics</i> , <b>2019</b> , 16, 43	5	6
213	Critical Steps to be Taken into Consideration Before Quantification of $\beta$ Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment. <i>Neurology and Therapy</i> , <b>2019</b> , 8, 129-145	4.6	6
212	Sex-specific associations with cerebrospinal fluid biomarkers in dementia with Lewy bodies. <i>Alzheimeris Research and Therapy</i> , <b>2020</b> , 12, 44	9	6
211	Nutritional Status Is Associated With Clinical Progression in Alzheimer's Disease: The NUDAD Project. <i>Journal of the American Medical Directors Association</i> , <b>2020</b> ,	5.9	5
210	Decline in cognitively complex everyday activities accelerates along the Alzheimer's disease continuum. <i>Alzheimeris Research and Therapy</i> , <b>2020</b> , 12, 138	9	5
209	Maximizing Safety in the Conduct of Alzheimer's Disease Fluid Biomarker Research in the Era of COVID-19. <i>Journal of Alzheimeris Disease</i> , <b>2020</b> , 76, 27-31	4.3	5
208	Amyloid- $\beta$ peptides in cerebrospinal fluid of patients with dementia with Lewy bodies. <i>Alzheimeris Research and Therapy</i> , <b>2019</b> , 11, 83	9	5
207	Short commentary on 'a consensus protocol for the standardization of cerebrospinal fluid collection and biobanking'. <i>Multiple Sclerosis Journal</i> , <b>2010</b> , 16, 129-32	5	5
206	Batch prepared protein standards for cerebrospinal fluid (CSF) biomarkers for neurodegeneration. <i>Journal of Neuroscience Methods</i> , <b>2010</b> , 193, 296-9	3	5
205	Why Is Amyloid- $\beta$ PET Requested After Performing CSF Biomarkers?. <i>Journal of Alzheimeris Disease</i> , <b>2020</b> , 73, 559-569	4.3	5
204	Nutritional status and structural brain changes in Alzheimer's disease: The NUDAD project. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2020</b> , 12, e12063	5.2	5
203	Onset of Preclinical Alzheimer Disease in Monozygotic Twins. <i>Annals of Neurology</i> , <b>2021</b> , 89, 987-1000	9.4	5
202	A neurologist's perspective on serum neurofilament light in the memory clinic: a prospective implementation study. <i>Alzheimeris Research and Therapy</i> , <b>2021</b> , 13, 101	9	5
201	Stability of Progranulin Under Pre-Analytical Conditions in Serum and Cerebrospinal Fluid. <i>Journal of Alzheimeris Disease</i> , <b>2016</b> , 53, 107-16	4.3	5

200	The inflammatory marker GDF-15 is not independently associated with late-life depression. <i>Journal of Psychosomatic Research</i> , <b>2016</b> , 83, 46-9	4.1	5
199	Four subgroups based on tau levels in Alzheimer's disease observed in two independent cohorts. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , 13, 2	9	5
198	CDH6 and HAGH protein levels in plasma associate with Alzheimer's disease in APOE $\epsilon$ carriers. <i>Scientific Reports</i> , <b>2020</b> , 10, 8233	4.9	4
197	Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 76, 1061-1070	4.3	4
196	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy. <i>PLoS ONE</i> , <b>2020</b> , 15, e0226784	3.7	4
195	Assessing the Pre-Analytical Stability of Small-Molecule Metabolites in Cerebrospinal Fluid Using Direct-Infusion Metabolomics. <i>Metabolites</i> , <b>2019</b> , 9,	5.6	4
194	Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2019</b> , 5, 492-500	6	4
193	Recent progress in omics-driven analysis of MS to unravel pathological mechanisms. <i>Expert Review of Neurotherapeutics</i> , <b>2013</b> , 13, 1001-16	4.3	4
192	Can agrin cerebrospinal fluid concentration be used as an early biomarker for Alzheimer's disease?. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2015</b> , 1, 75-80	5.2	4
191	Biomarkers for Alzheimer's disease. Which way to go?. <i>Neurobiology of Aging</i> , <b>2004</b> , 25, 695-6	5.6	4
190	Plasma p-tau217: from 'new kid' to most promising candidate for Alzheimer's disease blood test. <i>Brain</i> , <b>2020</b> , 143, 3170-3172	11.2	4
189	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , <b>2020</b> , 77, 1353-1368	4.3	4
188	Replication study of plasma proteins relating to Alzheimer's pathology. <i>Alzheimer's and Dementia</i> , <b>2021</b> , 17, 1452-1464	1.2	4
187	Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis. <i>Multiple Sclerosis Journal</i> , <b>2021</b> , 13524585211010097	5	4
186	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. <i>Alzheimer's and Dementia</i> , <b>2021</b> , 17, 1628-1640	1.2	4
185	Design of the NL-ENIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2016</b> , 2, 233-240	6	4
184	Cerebrospinal fluid N-224 tau helps discriminate Alzheimer's disease from subjective cognitive decline and other dementias. <i>Alzheimer's Research and Therapy</i> , <b>2021</b> , 13, 38	9	4
183	O3-09-06: A PROTOTYPE SIMOA ASSAY QUANTIFYING PLASMA AMYLOID BETA 1-42 AND 1-40 ISOFORMS CAN DIFFERENTIATE PARTICIPANTS WITH AD FROM HEALTHY CONTROL SUBJECTS <b>2018</b> , 14, P1039-P1039		4

182	Using cerebrospinal fluid amyloid-beta(1-42) in the memory clinic: Concordance with PET and use of biomarker ratios across immunoassays. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e045128	1.2	3
181	A biorepository for the in-depth validation of pre-analytical sample handling effects on novel blood-based biomarkers for Alzheimer's disease: The first results. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e045763	1.2	3
180	Gray matter network differences between behavioral variant frontotemporal dementia and Alzheimer's disease. <i>Neurobiology of Aging</i> , <b>2017</b> , 50, 77-86	5.6	3
179	Importance of Pre-analytical Stability for CSF Biomarker Testing <b>2015</b> , 59-77		3
178	Targeting MicroRNA-485-3p Blocks Alzheimer's Disease Progression. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	3
177	Detecting amyloid positivity in early Alzheimer disease using plasma biomarkers. <i>Alzheimeris and Dementia</i> , <b>2021</b> , 17,	1.2	3
176	Blood platelet RNA enables the detection of multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2020</b> , 6, 2055217320946784	2	3
175	Contactin-1 Is Reduced in Cerebrospinal Fluid of Parkinson's Disease Patients and Is Present within Lewy Bodies. <i>Biomolecules</i> , <b>2020</b> , 10,	5.9	3
174	New CSF biomarkers on the block. <i>EMBO Molecular Medicine</i> , <b>2016</b> , 8, 1118-1119	12	3
173	Variations in consecutive serum neurofilament light levels in healthy controls and multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 47, 102666	4	3
172	Circulating metabolites are associated with brain atrophy and white matter hyperintensities. <i>Alzheimeris and Dementia</i> , <b>2021</b> , 17, 205-214	1.2	3
171	Genetics Contributes to Concomitant Pathology and Clinical Presentation in Dementia with Lewy Bodies. <i>Journal of Alzheimeris Disease</i> , <b>2021</b> , 83, 269-279	4.3	3
170	Neurogranin as biomarker in CSF is non-specific to Alzheimer's disease dementia. <i>Neurobiology of Aging</i> , <b>2021</b> , 108, 99-109	5.6	3
169	Comparing CSF amyloid-beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2021</b> , 13, e12182	5.2	3
168	Exercise-induced increase in blood-based brain-derived neurotrophic factor (BDNF) in people with multiple sclerosis: A systematic review and meta-analysis of exercise intervention trials.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0264557	3.7	3
167	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview.. <i>Alzheimeris and Dementia</i> , <b>2021</b> ,	1.2	3
166	High efavirenz levels but not neurofilament light plasma levels are associated with poor neurocognitive functioning in asymptomatic HIV patients. <i>Journal of NeuroVirology</i> , <b>2020</b> , 26, 572-580	3.9	2
165	Diurnal Cortisol Secretion Is Not Related to Multiple Sclerosis-Related Fatigue. <i>Frontiers in Neurology</i> , <b>2019</b> , 10, 1363	4.1	2

164	[P1043]: ALPHA-SYNUCLEIN SPECIES AS POTENTIAL CSF BIOMARKERS FOR DEMENTIA WITH LEWY BODIES <b>2017</b> , 13, P338-P338		2
163	[O3003]: LONGITUDINAL CEREBROSPINAL FLUID BIOMARKER TRAJECTORIES ALONG THE ALZHEIMER'S DISEASE CONTINUUM: A MULTICENTRE EUROPEAN STUDY <b>2017</b> , 13, P924		2
162	Cerebrospinal fluid anti-whole myelin antibodies are not correlated to magnetic resonance imaging activity in multiple sclerosis. <i>Journal of Neuroimmunology</i> , <b>2012</b> , 251, 103-6	3.5	2
161	Axonale schade bij multiple sclerose: oorzaken en biologische markerstoffen. <i>Neuropraxis</i> , <b>2007</b> , 11, 27-31		2
160	Soluble TAM receptors sAXL and sTyro3 predict structural and functional protection in Alzheimer's disease.. <i>Neuron</i> , <b>2021</b> ,	13.9	2
159	Biomarker Testing: Piercing the Fog of Alzheimer's and Related Dementia. <i>Biomedicine Hub</i> , <b>2020</b> , 5, 19-40	1.3	2
158	The global Alzheimer's Association round robin study on plasma amyloid [methods]. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2021</b> , 13, e12242	5.2	2
157	Fluid Biomarkers for Monitoring Structural Changes in Polyneuropathies: Their Use in Clinical Practice and Trials. <i>Neurotherapeutics</i> , <b>2021</b> , 1	6.4	2
156	Reply to "Usefulness of Plasma Amyloid as Prescreener of the Earliest Alzheimer Pathological Changes Depends on the Study Population". <i>Annals of Neurology</i> , <b>2020</b> , 87, 155	9.4	2
155	CSF Biomarkers Reflecting Protein Pathology and Axonal Degeneration Are Associated with Memory, Attentional, and Executive Functioning in Early-Stage Parkinson's Disease. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	2
154	Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein. <i>Frontiers in Aging Neuroscience</i> , <b>2021</b> , 13, 638718	5.3	2
153	Tissue Transglutaminase Expression Associates With Progression of Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2021</b> , 8,	9.1	2
152	Clinical Phenotypes of Behavioral Variant Frontotemporal Dementia by Age at Onset. <i>Journal of Alzheimeris Disease</i> , <b>2021</b> , 82, 381-390	4.3	2
151	The plasma peptides of Alzheimer's disease. <i>Clinical Proteomics</i> , <b>2021</b> , 18, 17	5	2
150	Serum Contactin-1 in CIDP: A Cross-Sectional Study. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , <b>2021</b> , 8,	9.1	2
149	P4-224: Alzheimer's Disease Patients With Osas History Have Higher CSF Tau Levels <b>2016</b> , 12, P1115-P1115		2
148	Lumbar puncture patient video increases knowledge and reduces uncertainty: An RCT. <i>Alzheimeris and Dementia: Translational Research and Clinical Interventions</i> , <b>2021</b> , 7, e12127	6	2
147	Risk of dementia in APOE4 carriers is mitigated by a polygenic risk score. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2021</b> , 13, e12229	5.2	2

146	Targeting hippocampal hyperactivity with real-time fMRI neurofeedback: protocol of a single-blind randomized controlled trial in mild cognitive impairment. <i>BMC Psychiatry</i> , <b>2021</b> , 21, 87	4.2	2
145	No Plasmatic Proteomic Signature at Clinical Disease Onset Associated With 11 Year Clinical, Cognitive and MRI Outcomes in Relapsing-Remitting Multiple Sclerosis Patients. <i>Frontiers in Molecular Neuroscience</i> , <b>2018</b> , 11, 371	6.1	2
144	Differential Expression of Tissue Transglutaminase Splice Variants in Peripheral Blood Mononuclear Cells of Primary Progressive Multiple Sclerosis Patients. <i>Medical Sciences (Basel, Switzerland)</i> , <b>2018</b> , 6,	3.3	2
143	CSF Proteomic Alzheimer's Disease-Predictive Subtypes in Cognitively Intact Amyloid Negative Individuals. <i>Proteomes</i> , <b>2021</b> , 9,	4.6	2
142	Neurofilament light chain and glial fibrillary acidic protein levels in metachromatic leukodystrophy. <i>Brain</i> , <b>2021</b> ,	11.2	2
141	Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals. <i>Brain Communications</i> , <b>2021</b> , 3, fcab201	4.5	2
140	BDNF-Met polymorphism and amyloid-beta in relation to cognitive decline in cognitively normal elderly: the SCIENCE project. <i>Neurobiology of Aging</i> , <b>2021</b> , 108, 146-154	5.6	2
139	Identification of plasma proteome signatures associated with ATN framework using SOMAscan. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e036954	1.2	1
138	Mild cognitive impairment with Lewy bodies: Clinical characteristics and risk factors for progression. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e039094	1.2	1
137	Prediction of amyloid PET status using the LUMIPULSE G βamyloid ratio (1-42/1-40). <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e046006	1.2	1
136	International initiative for harmonization of cerebrospinal fluid diagnostic comments in Alzheimer's disease. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e047209	1.2	1
135	CSF proteomic profiling of mild cognitive impairment individuals with suspected non-Alzheimer's disease pathophysiology. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e047247	1.2	1
134	P2-166: Retinal Thickness in Alzheimer's Disease: A Potential Diagnostic Biomarker? Evidence from an Amyloid Proven Early Onset Alzheimer's Disease Cohort <b>2016</b> , 12, P678-P679		1
133	O5-07-02: Personalized Risk Estimates for Mci Patients: Taking Biomarkers Into the Clinic <b>2016</b> , 12, P393-P393		1
132	[IC-P-005]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOID-β AND [18F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS <b>2017</b> , 13, P13-P14		1
131	[P2B38]: ARE NEUROFILAMENT LIGHT CHAIN AND WHITE MATTER INTEGRITY RELATED BIOMARKERS FOR FAMILIAL FRONTOTEMPORAL DEMENTIA? <b>2017</b> , 13, P751-P752		1
130	O4-11-04: Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lp feasibility study <b>2015</b> , 11, P297-P297		1
129	Fluid and Tissue Biomarkers of Lewy Body Dementia: Report of an LBDA Symposium.. <i>Frontiers in Neurology</i> , <b>2021</b> , 12, 805135	4.1	1

128	Cerebrospinal fluid total tau levels indicate aberrant neuronal plasticity in Alzheimer's disease <b>2020</b>		1
127	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset		1
126	The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis.. <i>Multiple Sclerosis and Related Disorders</i> , <b>2022</b> , 57, 103364	4	1
125	Contribution of genetic and environmental factors to the onset of preclinical Alzheimer's disease - a monozygotic twin study		1
124	Neurofilament light chain as biomarker in idiopathic intracranial hypertension. <i>Cephalalgia</i> , <b>2020</b> , 40, 1346-1354	6.1	1
123	Plasma Amyloid-Beta Levels in a Pre-Symptomatic Dutch-Type Hereditary Cerebral Amyloid Angiopathy Pedigree: A Cross-Sectional and Longitudinal Investigation. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
122	Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , <b>2021</b> , 7, 20552173211013831	2	1
121	Use of Alzheimer's Disease Cerebrospinal Fluid Biomarkers in A Tertiary Care Memory Clinic. <i>Canadian Journal of Neurological Sciences</i> , <b>2021</b> , 1-7	1	1
120	Ultrasensitive immunoassay allows measurement of serum neurofilament heavy in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , <b>2021</b> , 50, 102840	4	1
119	The natural history of primary progressive aphasia: beyond aphasia. <i>Journal of Neurology</i> , <b>2021</b> , 1	5.5	1
118	Concatenating plasma p-tau to Alzheimer's disease. <i>Brain</i> , <b>2021</b> , 144, 14-17	11.2	1
117	P1-247: CEREBROSPINAL FLUID NEUROFILAMENT LIGHT PROTEIN AS A DIFFERENTIAL DIAGNOSIS BIOMARKER IN NEUROLOGICAL DISEASES: A SYSTEMATIC REVIEW AND METAANALYSIS <b>2018</b> , 14, P373-P373		1
116	Dopamine signaling modulates microglial NLRP3 inflammasome activation: implications for Parkinson's disease.. <i>Journal of Neuroinflammation</i> , <b>2022</b> , 19, 50	10.1	1
115	Serum neurofilament light chain, contactin-1 and complement activation in anti-MAG IgM paraprotein-related peripheral neuropathy.. <i>Journal of Neurology</i> , <b>2022</b> , 1	5.5	1
114	NT-proBNP and sRAGE levels in early rheumatoid arthritis.. <i>Scandinavian Journal of Rheumatology</i> , <b>2022</b> , 1-7	1.9	1
113	Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer's disease.. <i>Molecular Neurodegeneration</i> , <b>2022</b> , 17, 27	19	1
112	Clinical reporting following the quantification of cerebrospinal fluid biomarkers in Alzheimer's disease: An international overview. <i>Alzheimeris and Dementia</i> , <b>2021</b> , 17,	1.2	1
111	Development of an ultrasensitive multiplex assay for simultaneous detection of A $\beta$ -42, A $\beta$ -40, GFAP and NF-L in blood. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e043506	1.2	0



110	Cerebrospinal fluid proteomic profiles predict progression to dementia in prodromal AD. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e045230	1.2	o
109	Identifying and predicting heterogeneity in cognitive decline among individuals with prodromal Alzheimer's disease using a latent class analysis. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e045829	1.2	o
108	Associations Between Nutrient Intake and Corresponding Nutritional Biomarker Levels in Blood in a Memory Clinic Cohort: The NUDAD Project. <i>Journal of the American Medical Directors Association</i> , <b>2020</b> , 21, 1436-1438	5.9	o
107	Inflammatory and Neuronal Biomarkers Associated With Retinal Thinning in Pediatric HIV <b>2017</b> , 58, 5985-5992		o
106	Grey matter network markers identify individuals with prodromal Alzheimer's disease who will show rapid clinical decline.. <i>Brain Communications</i> , <b>2022</b> , 4, fcac026	4.5	o
105	LDL cholesterol and uridine levels in blood are potential nutritional biomarkers for clinical progression in Alzheimer's disease: The NUDAD project. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2020</b> , 12, e12120	5.2	o
104	Effect of driving speed on target visibility under mesopic conditions using a driving simulator. <i>Lighting Research and Technology</i> , <b>2021</b> , 53, 231-248	2	o
103	Biomarker testing in MCI patients-deciding who to test. <i>Alzheimeris Research and Therapy</i> , <b>2021</b> , 13, 14	9	o
102	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset.. <i>Frontiers in Aging Neuroscience</i> , <b>2022</b> , 14, 840651	5.3	o
101	Clinical application of CSF biomarkers for Alzheimer's disease: From rationale to ratios.. <i>Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , <b>2022</b> , 14, e12314	5.2	o
100	CSF proteomic changes in pre-preclinical Alzheimer's disease: A monozygotic twin study. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e038966	1.2	
99	Relationship between clinical symptomatology and disease burden in dementia with Lewy bodies: An overview of the DEvELOP baseline results. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e039306	1.2	
98	Single-cell profiling of circulating and brain-resident immune cells in a mouse model for amyloidosis and in aged mice. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e041789	1.2	
97	Polygenic risk score for Alzheimer's disease is related to amyloid positivity in subjective cognitive decline: The SCIENCE project. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e042116	1.2	
96	BDNF-Met polymorphism on top of amyloid pathology predisposes for faster cognitive decline in cognitively normal elderly: The SCIENCE Project. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e042728	1.2	
95	Localization and protein levels of YKL-40 in postmortem brain of frontotemporal dementia and Alzheimer's disease cases. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e044523	1.2	
94	Serum glial fibrillary acidic protein and neurofilament light as prognostic biomarkers for clinical progression in subjective cognitive decline: The SCIENCE project. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e044783	1.2	
93	Trajectories of decline in cognitively complex everyday activities across the Alzheimer's disease continuum. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e044787	1.2	

92	Comparison of two analytical platforms for blood-based surrogate biomarkers of amyloid pathology. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e045110	1.2
91	Amyloid aggregation and subsequent memory decline over time in cognitively intact older identical twins. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e045112	1.2
90	Serum neurofilament light in memory clinic practice. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e045155	1.2
89	Amyloid pathology, but not vascular pathology, is associated with risk of incident dementia in non-demented memory clinic participants. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e045196	1.2
88	Plasma biomarkers predict amyloid pathology in cognitively unimpaired individuals. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e045470	1.2
87	Educational video increases patients' knowledge regarding the lumbar puncture procedure: Results of a randomized controlled trial in clinical practice. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e045719	1.2
86	Plasma amyloid- $\beta$ oligomerization assay as a screening test for abnormal amyloid status. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e045754	1.2
85	Comparative diagnostic performance of plasma P-tau217 and P-tau181 in Alzheimer's disease and frontotemporal lobar degeneration and correlations with [18F]Flortaucipir-PET uptake. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e045755	1.2
84	CSF biomarkers for frontotemporal dementia and its pathological subtypes. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e045851	1.2
83	Synaptic proteins relate to memory scores in preclinical Alzheimer's disease and cognitively healthy controls depending on amyloid. <i>Alzheimeris and Dementia</i> , <b>2020</b> , 16, e046102	1.2
82	S4-01-01: Cross-Sectional Studies of Plasma Proteomic Biomarkers Relating to Pet Amyloid and CSF Amyloid and Tau <b>2016</b> , 12, P321-P321	
81	P2-335: Prevalence of Preclinical Alzheimer's Disease in Patients with Subjective Cognitive Decline: Comparison of Three European Memory Clinic Samples <b>2016</b> , 12, P770-P771	
80	Cerebrospinal Fluid Amyloid- $\beta$ Subtypes in Confirmed Frontotemporal Lobar Degeneration Cases: A Pilot Study. <i>Journal of Alzheimeris Disease</i> , <b>2019</b> , 71, 15-20	4.3
79	S4-01-04: INTERNATIONAL STANDARDIZATION TO OBTAIN THE BEST POSSIBLE CSF BIOMARKERS <b>2014</b> , 10, P239-P239	
78	O5-05-04: MATRIX METALLOPROTEINASES IN RELATION TO ALZHEIMER'S DISEASE AND CAA <b>2014</b> , 10, P300-P300	
77	P4-278: IDENTIFICATION OF NOVEL DIAGNOSTIC CSF PROTEIN BIOMARKERS FOR FTD WITH HIGH DISCRIMINATORY POWER <b>2014</b> , 10, P886-P886	
76	P4-273: CEREBROSPINAL FLUID NEUROGRANIN AS A PROGNOSTIC MARKER IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE <b>2014</b> , 10, P884-P884	
75	P3-072: Are relations between ApoE genotype and ad-related pathology in nondemented elderly mediated by CSF apolipoproteins? <b>2015</b> , 11, P644-P644	

- 74 O1-03-03: Olfactory dysfunction may predict Alzheimer's disease related tau pathology in cerebrospinal fluid (CSF) **2015**, 11, P130-P130
- 73 O4-03-01: Early detection of Alzheimer's disease (AD)-related amyloid and tau pathology: A computerized versus a paper-and-pencil memory test **2015**, 11, P272-P272
- 72 P2-298: Altered plasma and CSF levels of nutrients that enhance neuronal phospholipid synthesis in Alzheimer's disease: A retrospective cohort study **2015**, 11, P606-P607
- 71 O10901: Diagnostic impact of CSF biomarkers for Alzheimer's disease in a memory clinic setting **2013**, 9, P144-P145
- 70 [P4046]: NEUROFILAMENT LIGHT CHAIN AND PHOSPHOTAU/TAU RATIO AS CSF BIOMARKERS IN FRONTOTEMPORAL DEMENTIA **2017**, 13, P1313-P1314
- 69 [P4051]: ALPHA-SYNUCLEIN BIOMARKER ANALYSIS: ANALYTICAL PERFORMANCE AND INTER-LABORATORY PRECISION USING A NEW COLORIMETRIC ELISA **2017**, 13, P1316-P1316
- 68 [P2045]: AMYLOID VISUALIZATION IN THE RETINA OF ALZHEIMER'S DISEASE PATIENTS WITH CURCUMIN **2017**, 13, P705-P706
- 67 [P3061]: GRANULOCYTES: KEY PLAYERS IN PERIPHERAL A $\beta$  CLEARANCE? **2017**, 13, P995-P996
- 66 [P3026]: PROFILING PERIPHERAL METABOLIC DYSREGULATION IN ALZHEIMER'S DISEASE: THE ADDED VALUE OF MULTIPLE SIGNATURES **2017**, 13, P1024-P1025
- 65 [IC-P-055]: EFFECT OF APOE- $\epsilon$  ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER'S DISEASE **2017**, 13, P45-P46
- 64 [IC-P-058]: TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS **2017**, 13, P47-P48
- 63 [P1050]: DECISION TREE ANALYSIS REVEALS TWO CUT-OFF LEVELS FOR AMYLOID BETA IN EARLY AD DIAGNOSIS **2017**, 13, P342-P343
- 62 [P1076]: BRI2 DEMENTIA PATHWAY IN CSF, IMPROVING DETECTION THROUGH ULTRASENSITIVE SIMOA TECHNOLOGY **2017**, 13, P355-P355
- 61 [P2003]: SPPL2B: A NOVEL PROTEIN RELATED TO TAU PATHOLOGY IN ALZHEIMER'S DISEASE? **2017**, 13, P684-P684
- 60 [P2007]: CONCORDANCE BETWEEN CEREBROSPINAL FLUID AMYLOID- $\beta$  AND [18F]FLORBETABEN PET IN AN UNSELECTED COHORT OF MEMORY CLINIC PATIENTS **2017**, 13, P688-P688
- 59 [P2042]: PROTEOMICS IDENTIFICATION OF NOVEL CEREBROSPINAL FLUID BIOMARKER CANDIDATES OF DEMENTIA WITH LEWY BODIES **2017**, 13, P704-P704
- 58 [P2049]: CONTACTIN-1 IN CSF DISCRIMINATES DEMENTIA WITH LEWY BODIES (DLB) FROM AD AND NON-DEMENTED CONTROLS **2017**, 13, P708-P708
- 57 [P2035]: EFFECT OF APOE  $\epsilon$  ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER'S DISEASE **2017**, 13, P748-P750

- 56 [F10304]: BIOMARKER-BASED PERSONALIZED RISK ESTIMATES FOR PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE **2017**, 13, P177
- 55 [O10503]: CSF AMYLOID BETA 1 $\beta$ 2 LEVELS OBTAINED OVER 15 YEARS SHOW A DIAGNOSIS-DEPENDENT UPWARD DRIFT **2017**, 13, P198-P199
- 54 [O10504]: CLINICAL PERFORMANCE OF NEUROGRANIN AS A CEREBROSPINAL FLUID BIOMARKER FOR ALZHEIMER'S DISEASE: AN ASSAY COMPARISON STUDY **2017**, 13, P199
- 53 [O20101]: CHARACTERIZING INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE: THE SUBJECTIVE COGNITIVE IMPAIRMENT COHORT (SCIENCE) **2017**, 13, P547-P548
- 52 [O20501]: TWIN CORRELATIONS FOR AMYLOID PATHOLOGY MEASURED WITH POSITRON EMISSION TOMOGRAPHY AND IN CEREBROSPINAL FLUID IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS **2017**, 13, P559-P560
- 51 [O20006]: PROGNOSIS OF CLINICAL PROGRESSION IN SUBJECTIVE COGNITIVE DECLINE USING A CLINICAL DECISION SUPPORT SYSTEM **2017**, 13, P579
- 50 [P2094]: USING EMERGING CEREBROSPINAL FLUID MARKERS TO CHARACTERIZE SUSPECTED NON-ALZHEIMER'S DISEASE PATHOPHYSIOLOGY (SNAP) IN INDIVIDUALS WITH MILD COGNITIVE IMPAIRMENT **2017**, 13, P680-P681
- 49 [P3075]: PLEIOTROPHIN, A NEW BIOMARKER FOR AD, IDENTIFIED USING A NOVEL STRATEGY IN CLINICAL PROTEOMICS **2017**, 13, P960-P961
- 48 P1-180: Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease **2015**, 11, P414-P414
- 47 Guidelines on Cerebrospinal Fluid Analysis **2015**, 407-428
- 46 P1-120: Standardization of a method for diagnostic biomarker validation for neurodegenerative diseases: App assays as example **2015**, 11, P387-P387
- 45 P4-242: A case-control cohort study to define a threshold for the tau/abeta42 ratio in cerebrospinal fluid optimized for diagnosis of Alzheimer's disease **2015**, 11, P873-P873
- 44 O4-11-01: Multicentre performance evaluation of a novel, fully automated electrochemiluminescence immunoassay for the quantitation of A $\beta$ (1 $\beta$ 2) in human cerebrospinal fluid **2015**, 11, P295-P296
- 43 P3-142: Alzheimer's biomarkers in daily practice (ABIDE): Study design **2015**, 11, P679-P680
- 42 O1-07-02: Alzheimer's disease core biomarkers and prediction of dementia in MCI: The effect of age at onset **2015**, 11, P140-P142
- 41 O3-14-02: Assessing underlying Alzheimer's disease pathology in MCI patients from the amsterdam dementia cohort by use of the predictad software tool **2015**, 11, P254-P255
- 40 O5-05-03: Neurogranin, a CSF biomarker for synaptic loss, predicts decline to dementia due to Alzheimer's disease **2015**, 11, P326-P326
- 39 Konsensusprotokoll zur Standardisierung von Entnahme und Biobanking des Liquor cerebrospinalis1 / A consensus protocol for the standardisation of cerebrospinal fluid collection and biobanking. *Laboratoriums Medizin*, **2010**, 34, 1-12

- 38 Pre-analytical sample handling effects on blood cytokine levels: quality control of a COVID-19 biobank. *Biomarkers in Medicine*, **2021**, 15, 987-997 2.3
- 37 IC-03-02: Grey Matter Connectivity is Associated with Clinical Progression in Non-Demented, Amyloid Positive Patients **2016**, 12, P9-P10
- 36 O3-08-01: Grey Matter Connectivity is Associated with Time to Clinical Progression in Mild Cognitive Impairment, Independent of Amyloid Status **2016**, 12, P303-P303
- 35 IC-P-103: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non-Demented Stages of Alzheimer's Disease **2016**, 12, P78-P79
- 34 P3-144: Cognitive Subtypes Identified Using Nonnegative Matrix Factorisation in Four Large Alzheimer's Disease Dementia Cohorts **2016**, 12, P873-P874
- 33 P4-112: Amyloid Levels in the Normal Range are Predictive for Incident Dementia in Non-Demented Elderly **2016**, 12, P1055-P1056
- 32 O1-01-01: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non-Demented Stages of Alzheimer's Disease **2016**, 12, P169-P170
- 31 O1-05-02: Effects of Up to 14 Years of Biobank Storage of CSF Biomarkers AB42, TTAU, and PTAU **2016**, 12, P183-P183
- 30 O4-09-04: Towards Data-Driven Medicine in Differential Diagnostics of Neurodegenerative Diseases **2016**, 12, P355-P355
- 29 O5-05-03: Novel CSF Biomarkers Discriminating FTLD-TDP from Non-Demented Controls **2016**, 12, P388-P388
- 28 P1-174: Cost-Efficient Differential Diagnostics of Neurodegenerative Diseases Using A Stratified Approach **2016**, 12, P469-P470
- 27 gMS-Classifer1 does not predict disability progression in multiple sclerosis. *Multiple Sclerosis Journal*, **2019**, 25, 1010-1011 5
- 26 Pre-Analytical Processing and Biobanking Protocol for CSF Samples. *NeuroMethods*, **2021**, 137-145 0.4
- 25 O1-10-06: CONTACTIN-1 HAS ADDED VALUE FOR DISCRIMINATION OF DEMENTIA WITH LEWY BODIES FROM ALZHEIMER'S DISEASE AND PARKINSON'S DISEASE **2018**, 14, P245-P246
- 24 F2-02-04: NEUROFILAMENTS TO MEASURE TREATMENT EFFICACY IN MS **2018**, 14, P604-P604
- 23 P2-248: CONTACTIN-2 AS A POTENTIAL BIOMARKER FOR MILD COGNITIVE IMPAIRMENT **2018**, 14, P768-P768
- 22 P2-228: PRE-ANALYTICAL STABILITY OF NOVEL CEREBROSPINAL FLUID BIOMARKERS FOR DEMENTIA **2018**, 14, P755-P756
- 21 O2-04-02: LONGITUDINAL COGNITIVE TRAJECTORIES OF PATIENTS WITH DISCORDANT CSF AND PET AMYLOID BIOMARKERS **2018**, 14, P621-P622

- 20 P1-525: AMYLOID AGGREGATION IS ASSOCIATED WITH DECLINE ON DIGIT SPAN BACKWARD IN COGNITIVELY NORMAL ELDERLY MONOZYGOTIC TWINS **2018**, 14, P533-P533
- 19 P1-297: METABOLIC BLOOD-BASED BIOMARKERS RELATE TO BRAIN ATROPHY AND WHITE MATTER HYPERINTENSITIES IN ALZHEIMER'S DISEASE **2018**, 14, P401-P403
- 18 P3-289: HARMONIZATION OF SCD OPERATIONALIZATION ACROSS DIFFERENT MEMORY CLINIC SETTINGS: THE EURO-SCD STUDY **2018**, 14, P1191-P1191
- 17 O2-09-03: DIAGNOSTIC PERFORMANCE OF ELECSYS IMMUNOASSAYS FOR CEREBROSPINAL FLUID ALZHEIMER'S DISEASE BIOMARKERS IN A NON-ACADEMIC MULTICENTER MEMORY CLINIC COHORT: THE ABIDE PROJECT **2018**, 14, P641-P642
- 16 P3-264: UNBIASED METHOD TO DETERMINE CUT-POINTS FOR CSF TOTAL TAU LEVELS REVEALS PRESENCE OF BIOLOGICAL SUBTYPES IN A LARGE ALZHEIMER'S DISEASE POPULATION **2018**, 14, P1176-P1177
- 15 DT-02-02: NOVEL ULTRASENSITIVE IMMUNOASSAY DETECTING P-TAU THR217 COMPLETELY DISTINGUISHES ALZHEIMER'S DISEASE FROM FRONTOTEMPORAL LOBAR DEGENERATION **2018**, 14, P1669-P1669
- 14 O2-14-04: IDENTIFYING BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA AMONG PATIENTS WITH A LATE-ONSET FRONTAL LOBE SYNDROME: SUMMARY RESULTS OF THE LOF STUDY **2018**, 14, P657-P658
- 13 O2-15-06: CSF AMYLOID- $\beta$  PEPTIDES IN DEMENTIA WITH LEWY BODIES AND ALZHEIMER'S DISEASE **2018**, 14, P663-P664
- 12 O3-14-03: IDENTIFICATION OF NOVEL CEREBROSPINAL FLUID BIOMARKER CANDIDATES FOR DEMENTIA WITH LEWY BODIES: A PROTEOMIC APPROACH **2018**, 14, P1060-P1060
- 11 O2-15-04: ROBUST INDIVIDUALIZED PREDICTION MODELS WHICH ARE APPLICABLE ACROSS DIFFERENT COHORTS **2018**, 14, P661-P662
- 10 O5-01-03: ATROPHY SUBTYPES IN ALZHEIMER'S DISEASE IDENTIFIED THROUGH NON-NEGATIVE MATRIX FACTORIZATION **2018**, 14, P1638-P1639
- 9 P2-284: NUTRITIONAL MARKERS ASSOCIATED WITH CLINICAL PROGRESSION IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT AND SUBJECTIVE COGNITIVE DECLINE: THE NUDAD STUDY **2018**, 14, P789-P790
- 8 F4-08-01: PLASMA AMYLOID AS A PRE-SCREENING TOOL FOR AMYLOID POSITIVITY IN SUBJECTIVE COGNITIVE DECLINE **2018**, 14, P1394-P1394
- 7 O2-09-04: HARMONIZATION OF IMMUNOCHEMICAL METHODS FOR MEASUREMENT OF  $\beta$ SYNUCLEIN IN HUMAN CEREBROSPINAL FLUID: A ROUND ROBIN STUDY APPROACH **2018**, 14, P642-P642
- 6 A Cystatin C Cleavage ELISA Assay as a Quality Control Tool for Determining Sub-Optimal Storage Conditions of Cerebrospinal Fluid Samples in Alzheimer's Disease Research. *Journal of Alzheimer's Disease*, **2021**, 83, 1367-1377 4.3
- 5 CSF proteomic signature predicts progression to Alzheimer's disease dementia.. *Alzheimer's and Dementia: Translational Research and Clinical Interventions*, **2022**, 8, e12240 6
- 4 Author Response: Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis.. *Neurology*, **2022**, 98, 471 6.5
- 3 Alzheimer's disease genetic risk variants show brain cell type-specific associations with protein levels in cerebrospinal fluid.. *Alzheimer's and Dementia*, **2021**, 17 Suppl 3, e049531 1.2

- 2 Immune protein levels in cerebrospinal fluid: Associations with memory scores across the AD spectrum.. *Alzheimeris and Dementia*, **2021**, 17 Suppl 3, e055451 1.2
- 1 Effects of age, amyloid, sex, and  $\tau$  on the CSF proteome in normal cognition.. *Alzheimeris and Dementia: Diagnosis, Assessment and Disease Monitoring*, **2022**, 14, e12286 5.2